Subject: : A survey to understand the prescribing pattern of statins and their COmbiNaTions by caRdiOLogists and physicians managing patients of dyslipidaemia (CONTROL Study)
Cardio vascular diseases (CVD) have become a growing burden across the globe and are highly prevalent, especially in the developing countries that alone account for 80% of the global CVD mortality. Dyslipidemia has been strongly associated with the pathophysiology of cardiovascular diseases (CVDs) and is a major independent risk factor for coronary artery disease (CAD), and associated cardiovascular events.
The prevalence of dyslipidemia varies geographically; although, it has been estimated that more than 50% of the adult population has dyslipidemia worldwide. Studies have shown that Asians have a higher prevalence of lipid abnormalities as compared to non- Asians, it has been observed that dyslipidemia in Asians, especially Indians, is atherogenic, with a higher prevalence of low HDL cholesterol and high triglycerides and a lower prevalence of high serum cholesterol
Statins have been shown to reduce atherosclerosis cardiovascular disease events in both secondary and primary prevention. Statins have a limited ability to impact the levels of triglycerides, high-density lipoprotein cholesterol (HDL-C), and conditional coronary heart disease risk factors such as C-reactive protein and lipoprotein A. This provides a rationale to consider the addition of other lipid-modifying agents in the treatment of patients with complex dyslipidemia and/or at high risk for coronary heart disease. Additionally, the addition of such agents may offer the opportunity to augment the LDL-lowering effects of statins to attain the desirable LDL-C targets.
The major challenge for use of cholesterol-lowering drugs is the problem of long-term non-adherence. Improving adherence will require fundamental changes in the current healthcare system in which patient monitoring and follow-up is often not a high priority.
The purpose of this survey is to understand the prescribing pattern of statins and their combinations by cardiologist and physicians for primary prevention of cardiovascular disease in patient with dyslipidaemia.
We invite you to participate in this study. On acceptance, you will need to capture the relevant data as mentioned in the standard Data Collection Form (DCF) provided, from the patient’s medical records (case papers and investigational reports – hereafter referred as source documents).
We would recommend you to capture data fulfilling the criteria as outlined in the protocol and whose relevant laboratory investigations are available for the preceding 3 months. We wish to inform you that the DCF will capture all data in de-identified form and any identifiable parameters which may potentially disclose the identity of the patient such as name or address will strictly not be captured so as to ensure we maintain patient confidentiality. We would encourage you to carefully fill all available information to the fullest as recommended in the DCF.
In alignment with good clinical research practices, an independent Contract Research Organization (CRO) will monitor this study and do the source data verification of the data captured in the DCF with copies of the patients’ source medical records (case papers and investigational reports) to ensure that the data entered in the DCFs are accurate and in alignment with the patients’ medical records. The study is approved by independent ethics committee.
If you agree to participate in the said study, we would request you to sign and return the enclosed reply along with your visiting card for accuracy of records.
|
}}){kind=logo}